Target intelligence / Profile preview

Hemagglutinin Protein of Influenza B Virus (HA)

Target: HA
Molecular classification: Class I viral fusion protein, Glycoprotein

Overview

Hemagglutinin (HA) is the most abundant glycoprotein on the surface of the influenza B virus. It plays a critical role in viral entry by binding to sialic acid-containing receptors on host cells and mediating fusion between the viral envelope and host cell membrane. HA is also the primary antigen recognized by the immune system, making it a major target for neutralizing antibodies and vaccine development.

Mechanism of action

Neutralizing antibody binding to block receptor attachment or membrane fusion

Biological functions

Receptor bindingMembrane fusionAntigen presentationViral entry

Disease associations

InfectionInfluenza

Safety considerations

Antigenic drift leading to vaccine evasion

Beyond the preview

Go deeper on Hemagglutinin Protein of Influenza B Virus (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin Protein of Influenza B Virus (HA).

Explore the full profile